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Effect of diabetes and aminoguanidine therapy on renal ad- been shown to inhibit advanced glycation end-product
vanced glycation end-product binding. (AGE) formation and cross-linking in the streptozocin
Background. Advanced glycation end-products (AGEs) diabetic rat [2]. Aminoguanidine does not interfere with
have been implicated in the pathogenesis of diabetic nephropa- the formation of Amadori products such as glycated he-thy, and aminoguanidine (AG) has been shown to decrease
moglobin (Hb), but acts to inhibit subsequent rearrange-the accumulation of AGEs in the diabetic kidney.
ments that are essential for cross-linking reactions [3].Methods. This study investigates changes in AGE binding
associated with diabetes in the rat kidney using in vitro and in Hemoglobin in the presence of glucose has been shown
vivo autoradiographic techniques. Male Sprague-Dawley rats in vivo to form advanced glycated Hb [4]. Furthermore,
were randomized into control and diabetic groups with and AG has been shown to decrease AGE-Hb, consistent
without AG treatment and were sacrificed after three weeks. with the action of AG being distal to the formationFrozen kidney sections (20 mm) were incubated with [125I]-AGE-
of glycated Hb (HbA1c) [4]. Advanced glycation end-RNase or [125I]-AGE-BSA. To localize the AGE binding site,
products have been implicated in a number of biologicalin vivo autoradiography was performed by injection of 15 mCi
of [125I]-AGE-BSA into the abdominal aorta of the rat. processes, particularly in the pathogenesis of diabetic
Results. Low-affinity binding sites specific for AGEs in the complications and aging [5].
renal cortex (IC50 5 0.28 mm) were detected by in vitro autoradi- The function of AGE-specific binding proteins has not
ography. There was a significant increase in [125I]-AGE binding been fully elucidated, although it has been suggestedin the diabetic kidney, which was prevented by AG treatment.
they may act as receptors and may lead to alterations inEmulsion autoradiography revealed that binding was localized
cell function [6, 7]. A number of AGE-binding proteinsprimarily to proximal tubules in the renal cortex. Renal AGE
have been identified. These include a 35 kDa receptor,levels, as assessed by fluorescence or by radioimmunoassay,
were increased after three weeks of diabetes. This increase was known as RAGE, which is a member of the immunoglob-
attenuated by AG therapy. ulin superfamily [8, 9]. Another AGE-binding protein is
Conclusions. AGE binding sites are present within the prox- a lactoferrin-like molecule that is noncovalently associ-
imal tubules of the kidney and appear to be modulated by ated with RAGE. At least four other AGE-binding pro-endogenous AGE levels. It remains to be determined if these
teins have been identified, including OST-40, 80K-H, Ga-binding sites represent receptors involved in clearance of
lectin 3 [10], and the antibacterial protein lysozyme [11].AGEs or are linked to pathogenic pathways that lead to the
development of diabetic nephropathy. This study has evaluated AGE binding sites in the kid-
ney, a site of diabetic complications that appears to involve
AGE-dependent pathways [2, 12], using both in vitro
and in vivo autoradiographic techniques. Furthermore,Advanced glycation is the nonenzymatic and irrevers-
the effects of diabetes and of AG therapy, maneuversible glycation of proteins and lipids [1]. The pathway for
associated with changes in endogenous AGE levels [13],nonenzymatic glycation begins with the interaction of
on [125I]-AGE binding were also assessed. To assess theglucose and biological proteins and is most prevalent in
relationship between AGE accumulation and [125I]-AGEproteins with a long half-life. Aminoguanidine (AG) has
binding in the kidney, AGE levels were simultaneously
measured in the kidney.
Key words: proximal tubule, AGEs, autoradiography, diabetic ne-
phropathy, glucose control, hemoglobin.
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were randomized into four groups: control, control with buffer made up of 10 mm HEPES, 100 mm NaCl, 5 mm
KCl, 5 mm MgCl2, 1 mm EGTA, and 0.5 mg/ml bacitracin.AG (2 g/liter in drinking water; Regis, Morton Grove, IL,
USA), diabetic (induced by intravenous injection of strep- Sections were dried at room temperature and were then
placed under x-ray film for two weeks. Competitive bind-tozocin 50 mg/kg after an overnight fast), and diabetic with
AG (1 g/liter in drinking water). Rats were sacrificed after ing studies were performed with varying concentrations
of unlabeled AGEs. Competition studies were also per-three weeks. Prior to sacrifice, rats were weighed, and blood
pressure was determined by tail cuff plethysmography formed with nonglycated proteins. Nonspecific binding
(NSB) was determined by the addition of 10 mm unlabeled[15]. Only rats with plasma glucose of more than 15 mmol/
liter were considered diabetic. For in vitro autoradiogra- AGEs (3200 tracer concentration). Data were obtained
from two sections of five different kidneys for each experi-phy, kidneys were removed and snap frozen in liquid
nitrogen, and 20 mm sections were cut on a cryostat and mental point and are shown as mean 6 sem. In a separate
series of experiments, cryostat sections were incubatedmounted on slides coated with gelatin (0.5%). For in vivo
autoradiography experiments, animals were infused with with a different radioligand, [125I]-AGE-RNase, and com-
petition studies were performed with unlabeled AGE-radiolabeled AGEs before sacrifice (discussed later here).
RNase, AGE-BSA, and native (nonglycated) BSA and
Preparation of advanced glycation end-products RNase.
Fraktion V, free fatty acid (FFA), bovine serum albu-
Emulsion autoradiographymin (BSA; Boehringer-Mannheim, Mannheim, Germany),
or ribonuclease A (RNase) (Sigma Pharmaceuticals, St. To localize AGE-binding sites, emulsion autoradiog-
raphy was performed. Following postincubation wash-Louis, MO, USA) was glycated in vitro by incubation at
378C for 120 days with 0.5 m glucose in 0.2 m sodium ing, sections were fixed at 48C for 30 minutes in 10%
neutral-buffered formalin (NBF). Sections were brieflyphosphate buffer. The solutions were sterilized by pas-
sage through a 0.2 mm millipore membrane filter into a dipped at 428C in LM-1 liquid emulsion (Amersham,
Bucks, UK) diluted 1:1 with distilled water, dried forvacuette (vacuum sealed sterile test tube). This filtering
step results in the removal of lower molecular weight one to two hours at 258C in less than 80% humidity. The
emulsions were then exposed for at least two weeks atsubstances, including free glucose.
48C before development. Sections were then stained with
Iodination of advanced glycation end-products hematoxylin and eosin.
Thirty micrograms of AGE-BSA or AGE-RNase were
In vivo autoradiographyiodinated using iodogen (1,3,4,6-tetrachloro-3a,6a-diphe-
nyl-glycouril; Pierce Chemical Co., Rockford, IL, USA). To define further cellular localization of [125I]-AGE
binding in the renal cortex, the tracer was infused in vivoThe mixture was allowed to react for 10 minutes. The
entire mixture was removed from the iodogen-coated in separate groups of rats. This approach has been used
when characterizing other binding sites because it is asso-tube and was then added to 200 ml of 0.2% phosphate-
buffered gelatin (PBG) [0.2% gelatin into phosphate- ciated with better preservation of morphology [16, 17].
Rats were anesthetized with pentobarbital sodium (Nem-buffered saline (PBS)]. The mixture, including the la-
beled protein, was separated in a previously prepared butal 50 mg/kg body wt), and the abdominal cavity was
opened with a midline incision. For infusion of [125I]-AGEs,10 ml Sephadex G50 column.
a 22-gauge catheter was inserted into the abdominal
In vitro autoradiography aorta below the renal arteries. For total binding studies,
rats were infused with approximately 15 mCi [125I]-AGE-Frozen tissues were cut at 20 mm on a cryostat at
2208C. Tissue sections were washed twice for 7.5 minutes BSA in 1 ml of 0.1 m PBS at pH 7.4. After 20 minutes
of circulation, the rats were perfused at systolic bloodin a preincubation buffer containing 10 mm N-2-hydroxy-
ethylpiperazine-N9-2-ethanesulfonic acid (HEPES), 100 pressure (approximately 140 mm Hg) with PBS for one
minute, followed by 2% glutaraldehyde for two minutes.mm NaCl, 5 mm KCl, 5 mm MgCl2, 1 mm ethyleneglycol-
bis-(b-amino-ethyl ether) N, N9-tetra acetic acid (EGTA), After perfusion fixation, one kidney was removed and
fixed in 10% neutral-buffered formalin overnight before0.1% BSA, and 0.5 mg/ml bacitracin. Tissue sections
were then incubated for three hours in incubation buffer, being embedded in paraffin. Nonspecific binding (NSB)
was performed in separate animals by infusion of excesswhich was made of prewash buffer and [125I]-AGE tracer.
Final counts in the incubation buffer were approximately (1025 m) unlabeled AGE proteins three minutes prior
to the infusion of the [125I]-AGE tracer. The procedure350 to 400 cpm/ml, with the total counts used being ap-
proximately 3.0 3 106 cpm and a final concentration of was then followed as mentioned earlier here. The other
kidney was frozen, and 20 mm sections were cut on aapproximately 2 pm of [125I]-AGE. Tissue sections were
washed first in preincubation buffer for four minutes, cryostat, then dried, and placed under x-ray film.
Paraffin-embedded sections were cut at 4 mm and werefollowed by two four-minute washes in postincubation
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Table 1. Characteristics of animal modelsdewaxed by incubation in histolene for four minutes and
then in decreasing ethanol followed by double-distilled Body weight Blood pressure Blood glucose
Group N g mm Hg mmol/literwater (ddH2O). The sections were dried at room temper-
Control 20 360616 11464 6.6 60.2ature and then were briefly dipped into LM-1 liquid
Control 1 AG 8 334 614 11663 5.4 60.2emulsion at 428C, diluted 1:1 with distilled water, dried
Diabetic 19 239611b 12963a 22.961.2b
for one to two hours at 258C at less than 80% humidity. Diabetic 1 AG 16 231617b 13464a 25.161.7b
Slides were incubated for approximately two weeks, were Abbreviation AG is aminoguanidine. Data are shown as mean 6 sem.
a P , 0.05, b P , 0.01 vs. Controldeveloped in Phenisol for two minutes, and were fixed in
Hypam for four minutes. After development, the slides
were counterstained with hematoxylin for two minutes
and eosin for 30 seconds. nal cortical homogenates were incubated for five hours
at room temperature with the AGE-BSA antibody andLectin staining
tracer at room temperature. Sheep antirabbit IgG was
To define if the renal tubular binding of [125I]-AGEs then added and incubated overnight at room temperature.
was localized to distal or proximal tubules, kidney sec- Precipitation of proteins was carried out by an addition
tions were stained with lectin from phaseolus vulgaris of 8% polyethylene glycol. The minimum detectable con-
(PHA-E, red kidney bean) [18], which specifically stains centration of AGE-RNase was 250 ng/ml, and the closing
proximal tubules [19]. Sections were dewaxed through volume (CV) for this assay was 12.3% (N 5 21) at a
to double-distilled water, were then quenched with meth- concentration of 2000 ng AGE-RNase/mg protein. Ra-
anol for 20 minutes, and were washed three times with dioactivity was measured using a gamma counter (Can-
PBS. Endogenous sites were blocked by incubation with berra Packard Instruments, St. Louis, MO, USA), and
normal horse serum for 10 minutes. Tissue sections were the amount of AGEs present was expressed as ng AGE-
then exposed to lectin (1 mg/ml) for 60 minutes. Second- RNase. To determine the epitope reacting with our anti-
ary avidin-biotin complex (ABC) staining was then used body, competition studies were performed as previously
with 3,39-diaminobenzidine tetrahydrochloride (DAB) described [20]. These experiments indicated that the anti-
to localize lectin binding. body detects advanced glycated RNase, advanced gly-
cated BSA, and carboxy methyl lysine (CML)-containing
Measurement of advanced glycation end-products proteins, including CML-BSA and CML-collagen. How-
As previously described [2], in parallel experiments ever, the antibody does not detect native BSA, native
using the same protocol, the cortex of the left kidney RNase, or pentosidine.
was removed, minced, and suspended in PBS, followed
Analysis of resultsby centrifugation at 15,000 revolutions/min for 30 min-
utes at 48C. Lipid extraction was performed by the addi- All data are shown as mean 6 sem. The density of
tion of 5 ml of chloroform/methanol (2:1 vol:vol), fol- tracer binding was quantitated and analyzed by a com-
lowed by gentle shaking and overnight incubation at 48C. puter-aided image analysis system (Imaging Research,
The upper layer was removed, and the pellet was washed St. Catherines, Ontario, Canada). Because of the focal
three times with methanol and distilled water. The pellet nature of [125I]-AGE binding in the renal cortex, the
was then resuspended in 0.05 m acetic acid and 1 mg/ml mean of 20 to 25 quantitations was used for each kidney
pepsin, incubated for 18 hours at 48C to remove noncol- section. The Bmax, which represents binding site density,
lagenous proteins, and washed with 0.1 m CaCl2, 0.02 m and dissociation constant (Kd), which reflects the affinity
Tris-HCl (pH 7.6), and 0.05% toluene. Following diges- of the ligand to the receptor, were assessed by the com-
tion with type IV collagenase (0.1 mg/ml; Sigma) and puter program LIGAND [21]. The program SIGMA-
proteinase K (0.1 mg/ml; Sigma) for 72 hours at 378C, PLOT was used to determine the value for the half maxi-
the samples were centrifuged at 15,000 revolutions/min mal inhibitory concentration (IC50). Data were analyzed
for 30 minutes at 48C. The resulting supernatant was by analysis of variance on a Macintosh personal com-
then used to measure AGE levels. puter (Apple, Cupertino, CA, USA) using the StatViewt
Advanced glycation end-product levels in collagenase program (Abacus Concepts Inc., Berkeley, CA, USA). A
extracted renal homogenates were measured by specific P value of less than 0.05 was considered to be statistically
fluorescence (370 nm/440 nm ex/em) as previously de- significant.
scribed [2] and by a radioimmunoassay (RIA) developed
in our laboratory using an antibody directed against AGE-
RESULTSBSA [20]. Recent studies have revealed that this antibody
Characteristics of animalsdetects the nonfluorescent AGE, carboxy methyl lysine-
containing proteins [20]. AGE-RNase was used for prepa- Diabetes was associated with a reduced weight gain
and a marked increase in plasma glucose levels (Table 1).ration of tracer and standards. Collagenase-extracted re-
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Blood pressure was modestly elevated in the diabetic in proximal tubules (Fig. 5 A, B), as confirmed by colocal-
rats. AG did not influence body weight, plasma glucose, ization of grains representing [125I]-AGE binding and
or blood pressure. lectin (Fig. 5C).
To further explore the relationship between [125I]-AGE
[125I]-AGE binding in the kidney binding and AGEs, renal cortical AGE levels were mea-
Maximal binding of [125I]-AGEs was detected after two sured both by fluorescence and RIA. Within three weeks
hours at a concentration of approximately 2 pm (specific of experimental diabetes, there was a twofold increase
activity of 100 Ci/mmol). In both control and diabetic in AGEs as measured by either fluorescence (Fig. 6A)
rats, [125I]-AGE binding was observed in the renal cortex, or RIA (Fig. 6B). This increase in AGEs in the diabetic
medulla, and papilla (Fig. 1). There was also prominent rats was prevented by AG treatment. Aminoguanidine
[125I]-AGE binding in the kidneys at the corticomedullary did not significantly influence AGE levels in control rats.
junction. [125I]-AGE binding was inhibited in the pres-
ence of 1 3 1025 m unlabeled AGE [that is, nonspecific
DISCUSSIONbinding (NSB)], with NSB being less than 12% of maxi-
This study has identified a binding site for AGEs inmal binding (Fig. 1E). NSB was assessed using different
the proximal tubules of the rat kidney, which appearsnonradiolabeled forms of AGEs, including AGE-BSA
to be specific for AGEs. Both radiolabeled AGE-BSAand AGE-RNase.
and AGE-RNase bound to this site. Furthermore, unla-Using [125I]-AGE-BSA as the radioligand, AGE-BSA
beled AGE-BSA competed for the radioligand [125I]-competed for the tracer with a Kd of 1.95 3 1027 m in
AGE-RNase, and AGE-RNase competed for the ra-the renal cortex (Fig. 2). AGE-RNase competed for the
dioligand [125I]-AGE-BSA. Importantly, native BSA ortracer with a Kd of 2.03 3 1027 m. In contrast, native
RNase did not displace either radioligand. Because bothBSA and RNase did not displace the radioligand.
radioligands had a similar distribution within the kidneyUsing [125I]-AGE-RNase as the radioligand, unlabeled
and similar binding characteristics, it is likely that theyAGE-RNase and AGE-BSA competed for the tracer.
bound to the same binding site.Nonglycated BSA or RNase failed to compete with [125I]-
The number of proximal tubular AGE binding sitesAGE-RNase. The distribution of this tracer within the
identified in this study was increased in experimental dia-kidney and binding characteristics as obtained from analy-
betes. Furthermore, this increase in AGE binding wassis of the binding isotherms of the radioligand were similar
prevented by AG treatment in the diabetic rats. Althoughto those observed with [125I]-AGE-BSA (data not shown).
there was an increase in maximal binding (Bmax) in theDiabetes was associated with an increase in [125I]-AGE
diabetic kidney, there was no significant change in bind-binding after three weeks, particularly in the renal cortex
ing affinity. In this study, using both fluorescence and an(Figs. 1C and 3A). However, there was no difference in
RIA, which detects CML-containing proteins, it couldthe distribution of binding in the renal cortex, medulla,
be clearly demonstrated that within three weeks of in-or papilla between diabetic and control rats. Aminoguani-
duction of experimental diabetes that there is an increasedine treatment did not influence [125I]-AGE binding in
in AGE levels in the kidney that did not occur with AGcontrol rats but prevented the increase in [125I]-AGE bind-
treatment. The concurrent increase in AGE levels anding in diabetic rats (Fig. 3). A similar pattern of binding
AGE binding is consistent with the hypothesis that en-was observed in the renal medulla (Figs. 1D and 3B),
dogenous AGEs are able to induce AGE binding siteswith an increase in [125I]-AGE binding with diabetes and
in the kidney in experimental diabetes. Indeed, in blooda prevention of this increase by AG treatment (Fig. 3B).
vessels, it has been shown that increased expression ofAnalysis by the computer program LIGAND re-
AGE proteins, as seen in diabetes, is associated withvealed that there was an increase in the Bmax in diabetes
increased levels of the AGE receptor RAGE [22].(Fig. 3) but no change in the dissociation constant (Kd,
Gugliucci and Bendayan [23] have previously shown2.03 3 1027 m). Aminoguanidine decreased Bmax but did
that AGE-containing proteins injected into rats are reab-not change Kd.
sorbed by proximal tubules. Therefore, it could be con-By in vitro emulsion autoradiography, it was confirmed
sidered that AGE binding observed after in vivo injec-that the major renal cortical binding site was to tubules
tion represents nonspecific uptake by proximal tubularin all groups studied, (Fig. 4). The binding appeared to
cells. However, a similar pattern of distribution of thebe to proximal tubules. Therefore, to further localize
radioligand was observed in the in vitro autoradiographic[125I]-AGE binding in the cortex more accurately, in vivo
studies, and included repeated washes in buffer to dis-autoradiography was performed, supplemented by coun-
place endogenous ligands and proximal tubular enzymesterstaining with lectin from vaseolus vulgaris, which spe-
involved in nonspecific protein reabsorption by renalcifically stains proximal tubules. In vivo binding revealed
proximal tubular cells. In the in vivo as well as the inan almost threefold increase in renal cortex [125I]-AGE
vitro studies, excess unlabeled AGEs were associatedbinding in diabetes (control, 565 6 50; diabetic, 1448 6
with greater than 80% displacement of the radioligand,56 dpm/mm2, P , 0.01 vs. control). Furthermore, using
emulsion autoradiography, the major site of binding was a phenomenon not observed with the native protein.
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Fig. 1. Gross localization of 125I-AGE-BSA in vitro binding in the rat
kidney. (A) Total binding for control. (B) Control 1 aminoguanidine.
(C) Diabetic. (D) Diabetic 1 aminoguanidine. (E) Nonspecific binding.
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Fig. 2. Binding isotherms generated by in vitro incubation of tissue
sections with 125I-AGE-BSA with increasing concentrations of unlabeled
AGE-BSA (e), unlabeled AGE-RNase (s), native BSA (h), and
native Rnase (j). The y-axis represents binding density as quantitated
by the MCID program.
Although this study identified a renal proximal tubular
binding site in the kidney, it is difficult to determine if
this site represents one of the previously characterized
receptors or binding proteins for AGEs. Our own group
has localized the receptor for AGEs known as RAGE
in the kidney using immunohistochemical techniques
[24]. It is unlikely that the binding site characterized in
the current study is RAGE, because RAGE is localized
primarily to distal tubules and to a lesser extent glomeruli
rather than to proximal tubules.
In this study, diabetes was associated with increased
AGE binding. A preliminary report has suggested that
RAGE mRNA levels may be increased in experimental
diabetes mellitus [25]. However, a recent report has sug-
Fig. 3. In vitro 125I-AGE-BSA binding in the renal cortex (A) andgested that there is no up-regulation of RAGE mRNA
medulla (B). Data are shown as mean 6 sem. Abbreviations are: Con,levels in the db/db diabetic mouse [26]. Li et al and Yang control; diab, diabetic; AG, aminoguanidine. *P , 0.01 vs. control, †P ,
et al have identified three different AGE binding sites 0.01 vs. diabetic.
known as AGE-R1, AGE-R2, and AGE-R3 [10, 27],
and AGE-R2 and AGE-R3 have been reported to be
increased in mesangial cells from the NOD mouse model
The assessment of the binding isotherms revealed thatof diabetes [28]. There are no reports of these receptors
the AGE binding site was of low affinity, with a Kd inbeing present in proximal tubular cells. Over the last few
the nanomolar range. This is consistent with the bindingyears, several other AGE-binding proteins have been
characteristics that have been described for RAGE, asidentified, including lactoferrin and lysozyme [11, 29].
well as for several of the other cloned AGE binding sitesOf particular interest is the possibility that the proximal
[9, 27, 30]. However, one must be cautious in comparingtubular binding may represent AGEs binding to lyso-
the findings from in vitro autoradiographic studies tozyme. Further studies are warranted to explore the possi-
those using membrane-binding techniques. For example,bility that the AGE-binding site identified in this study
may represent one of the receptors described earlier here. the assessment of binding sites in the brain for the pan-
Youssef et al: Renal AGE binding in experimental diabetes 913
of AGEs are manifest early in experimental diabetes
mellitus [32, 33]. There was a tendency for the increase
in AGEs in the diabetic kidney to be greater, as assessed
by RIA when compared with fluorescence measure-
ments (Fig. 6). It should be noted that the RIA used in
this study also detects CML [20], a nonfluorescent AGE
[34]. Therefore, it is possible that CML-containing AGEs
are increased earlier than fluorescent, cross-linked AGEs
in response to chronic hyperglycemia in experimental
diabetes. Further studies are required to characterize the
chemical structure of the various AGEs formed in vivo
that are detected by the different assay methods.
It is difficult to determine if the AGE binding site
described in this study represents a clearance mechanism
or a pathway leading to tissue injury. Gugliucci and Ben-
dayan have suggested that the localization of AGE pep-
tides in the proximal tubular cells is increased in diabetes
and may lead to tubulointerstitial fibrosis [23]. More
recently, it has been shown that one of the AGEs that
circulates is localized to proximal tubules of rat kidney
[35]. These findings provide further evidence that AGEs,
including pentosidine, are reabsorbed by the proximal
tubules of the kidney, degraded or modified, and finally
excreted in the urine.
It has been demonstrated that AGEs can activate a
range of intracellular second messengers, including mito-
gen-activated protein kinase in a renal tubular cell line
[36]. This is consistent with the possibility that tubular
cells respond to AGEs and result in a cascade of intracel-
lular events, including expression of cytokines such as the
prosclerotic growth factor transforming growth factor-b
(TGF-b). Indeed, TGF-b has been shown to be induced
by exogenous AGEs [37] and in endogenous states of
increased AGEs such as experimental diabetes mellitus
[14]. Tubulointerstitial fibrosis is a well-known patholog-
ical feature occurring in association with glomeruloscle-
rosis in diabetic nephropathy [38].
Fig. 4. In vitro emulsion autoradiography that shows binding to renal It has been previously shown that several of the AGE-
tubules (t) but not to glomeruli (g). (A) Bright field (magnification binding proteins act as receptors and lead to a range of
3200). (B) Dark field (magnification 3200).
intracellular processes, including activation of cytokines,
that could cause tissue injury [39–42]. Our group has
previously shown that AG can retard the development
of experimental diabetic nephropathy [2]. In this study,creatic hormone, amylin, revealed significant differences
in the calculated affinity between membrane binding and AG treatment was associated with reduced AGE binding
in the kidney. If one assumes that this renal proximalin vitro auotradiographic studies [31].
In this study, AGEs were already elevated within three tubular binding site is involved in mediating tissue injury,
one could speculate that the renoprotective effects ofweeks of experimental diabetes mellitus. A similar early
rise in AGE levels was reported by our group in vessels AG may involve reduced expression of receptors, which
are mediating pathways relevant to the genesis of dia-from diabetic rats using the same RIA as well as by
immunohistochemistry [14, 24]. This suggests that AGEs betic complications. The role of AG in mediating reno-
protection in diabetes remains under clinical investiga-that are either fluorescent or CML-containing appear
early after the induction of diabetes mellitus. Hill et al tion [12]. Furthermore, a range of new inhibitors of
advanced glycation is now under development, includinghave reported accumulation of AGEs in skeletal muscle
arterioles within four to six weeks of experimental diabe- novel inhibitors of AGE formation [43] and cross-link
breakers that cleave preformed cross-links [44].tes [32]. Furthermore, it has been shown that the effects
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Fig. 5. In vivo emulsion autoradiography
that shows binding to proximal tubules (p) but
not to glomeruli (g) or distal tubules (d). (A)
Bright field (magnification 3200). (B) Dark
field (magnification 3200). (C) Bright field
with lectin counterstain (magnification 3400).
It cannot be excluded that the increase in AGE bind- in AGE clearance or in mediating potentially damaging
ing in diabetes represents a response to the increase in effects on the kidney relevant to the genesis of diabetic
circulating and local AGE levels observed with chronic nephropathy.
hyperglycemia. One could speculate that the increase in
AGE binding represents a protective mechanism, acti- ACKNOWLEDGMENTS
vated in response to AGE formation, that operates in the
The work from these studies was financially supported by grantsdiabetic kidney to clear potentially pathogenetic AGE
from the Juvenile Diabetes Foundation International, the National
proteins. Therefore, it remains to be determined if the Health and Medical Research Council, and the Australian Kidney
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distilled water; FFA, free fatty acid; Hb, hemoglobin; IC50, half maximal
inhibitory concentration; Kd, dissociation constant; LF-L, lactoferrin-
like; NBF, neutral buffered formalin; NSB, nonspecific binding; PBG,
phosphate buffered gelatin; PBS, phosphate buffered saline; RAGE,
AGE binding protein 35 kD receptor; RIA, radioimmunoassay; RNase,
ribonuclease A; SD, Sprague-Dawley; TGF-b, transforming growth
factor-b.
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